Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
2025;S0161-6420(25)00070-3
This analysis reviews publicly available data to help readers independently assess weight loss medication options
Continued Growth in GLP-1 Compounding Despite Regulatory Headwinds Despite the resolution of GLP-1 shortages and increased regulatory scrutiny, compounded prescriptions for semaglutide and tirzepatide continue to rise
Common pharmacological triggers include antihistamines, antidopaminergic antiemetics, most antidepressants (particularly selective serotonin reuptake inhibitors and tricyclic antidepressants), and some antipsychotic medications
NICE guidance (NG28) recommends considering GLP-1 receptor agonists for adults with type 2 diabetes when glycaemic targets are not achieved with other therapies, particularly in those with established cardiovascular disease or at high cardiovascular risk
, ,
US$ 25.24
US$ 23.30
US$ 22.27
US$ 22.67
